Stockscreener 앱 받기
120.69
3.94%
4.58
전일 마감가:
$116.11
열려 있는:
$121.05
하루 거래량:
1.92M
Relative Volume:
1.68
시가총액:
$12.03B
수익:
$2.24B
순이익/손실:
$385.90M
주가수익비율:
32.36
EPS:
3.73
순현금흐름:
$440.10M
1주 성능:
+4.93%
1개월 성능:
-17.27%
6개월 성능:
-20.01%
1년 성능:
-7.62%
1일 변동 폭
$118.57
$122.37
1주일 범위
$113.00
$122.37
52주 변동 폭
$110.95
$157.98
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
120.69 | 12.03B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now? - Insider Monkey
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality - Simply Wall St
Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Neurocrine Biosciences authorizes $500M share repurchase program - MSN
DSM Capital Partners LLC Has $127.30 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts - Benzinga
Huntington's Disease Market Growth to Accelerate in Forecast - openPR
Neurocrine Biosciences sets $500M share buyback plan By Investing.com - Investing.com South Africa
Neurocrine Biosciences sets $500M share buyback plan - Investing.com
Neurocrine Biosciences Approves $500 Million Share Repurchase Program -February 21, 2025 at 08:19 am EST - Marketscreener.com
Neurocrine Board Authorizes Share Repurchase ProgramQuick Facts - Nasdaq
Neurocrine Biosciences (NBIX) Announces $500M Share Buyback - StreetInsider.com
Can Neurocrine's New $500M Buyback Signal Even Stronger Growth Ahead? - StockTitan
Leerink Partnrs Issues Optimistic Outlook for NBIX Earnings - MarketBeat
Rice Hall James & Associates LLC Sells 6,785 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded to Buy Rating by StockNews.com - MarketBeat
AlphaCentric Advisors LLC Sells 18,816 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program - Marketscreener.com
Leerink Partnrs Has Pessimistic View of NBIX Q3 Earnings - MarketBeat
Ieq Capital LLC Increases Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Van ECK Associates Corp Buys 9,824 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
New York State Teachers Retirement System Cuts Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Vontobel Holding Ltd. Has $1.15 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Matt Abernethy Sells 2,558 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January - Insider Monkey
Neurocrine Biosciences chief legal officer sells $107,727 in stock - MSN
Neurocrine Biosciences' chief corporate affairs officer sells shares worth $208,387 - MSN
Neurocrine Biosciences CFO Matt Abernethy sells $115,908 in stock - MSN
Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts By Investing.com - Investing.com Nigeria
Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts - Investing.com
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Sees Large Drop in Short Interest - MarketBeat
Stanley Laman Group Ltd. Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences CHRO sells shares worth $181,129 - MSN
Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 5,844 Shares of Stock - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Trimmed by Allspring Global Investments Holdings LLC - MarketBeat
Julie Cooke Sells 1,551 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat
Neurocrine Biosciences chief legal officer sells $254,991 in stock - MSN
Stifel maintains Neurocrine Bio stock target, positive on Takeda deal - MSN
Savant Capital LLC Purchases Shares of 16,543 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano Sells 980 Shares - MarketBeat
Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 2,274 Shares of Stock - MarketBeat
Neurocrine Biosciences chief scientific officer sells $336,238 in stock - MSN
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Cut by Fiera Capital Corp - MarketBeat
Neurocrine Biosciences chief commercial officer sells $251,426 in stock - MSN
Neurocrine Biosciences director Sherwin sells $1.6m in stock - MSN
Neurocrine Biosciences CEO sells shares for $298,907 By Investing.com - Investing.com Australia
Neurocrine Biosciences chief corporate affairs officer sells $82,820 in stock - MSN
Neurocrine Biosciences chief commercial officer sells $115,940 in stock - MSN
Neurocrine Biosciences executive sells shares worth $82,792 - MSN
Neurocrine Biosciences director sells $681,913 in stock - MSN
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cooke Julie | Chief Human Resources Officer |
Feb 13 '25 |
Sale |
116.78 |
1,551 |
181,129 |
19,544 |
| GORMAN KEVIN CHARLES | Director |
Feb 13 '25 |
Option Exercise |
0.00 |
10,979 |
0 |
527,221 |
| GORMAN KEVIN CHARLES | Director |
Feb 13 '25 |
Sale |
116.69 |
5,844 |
681,914 |
521,618 |
| SHERWIN STEPHEN A | Director |
Feb 13 '25 |
Sale |
116.69 |
13,831 |
1,613,923 |
10,673 |
| ROBERTS EIRY | Chief Medical Officer |
Feb 13 '25 |
Option Exercise |
0.00 |
4,605 |
0 |
36,140 |
| ROBERTS EIRY | Chief Medical Officer |
Feb 13 '25 |
Sale |
116.85 |
1,718 |
200,742 |
34,252 |
| ROBERTS EIRY | Chief Medical Officer |
Feb 14 '25 |
Sale |
115.04 |
500 |
57,521 |
35,640 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '25 |
Option Exercise |
0.00 |
5,407 |
0 |
19,536 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '25 |
Sale |
116.79 |
2,879 |
336,239 |
16,846 |
| Lippoldt Darin | Chief Legal Officer |
Feb 13 '25 |
Option Exercise |
0.00 |
4,100 |
0 |
44,491 |
1.72%
0.51%
자본화:
|
볼륨(24시간):